Why You Cannot Stockpile Your Pet's Controlled Medication: What the Federal Text Actually Says

The kit pages on this site keep arriving at the same instruction: carry two weeks. Two weeks of food, two weeks of water, two weeks of the medication your animal takes every day. It is a reasonable target and it is achievable for most of what goes in a go-bag.

Then you get to the prescription bottle and the instruction stops working. Not because the reserve is a bad idea. Because a whole separate body of law sits between you and a larger quantity, that law names a different decision-maker for every piece of the problem, and the version of it that circulates most often is wrong in the same few places.

This page is about the text. What does federal law actually limit, and what does it leave alone? Which of the rules you have read are federal, which are your state’s, and which belong to a pharmacy chain or an insurance plan that nobody has named to you? And when a storm is coming and the reserve you wanted does not exist, what is the conversation that a veterinarian can actually act on?

One thing this page will not do is coach you toward a larger quantity. There is no phrasing trick here, no second prescriber, no early-fill workaround. Every one of those would be asking a professional to do something they are not permitted to do, and the ask would fail in a way that makes the next ask harder. What is here instead is the map: what the rule is, whose rule it is, and which question goes to which person. That is a lot more useful in August than a script is in September.

Two Questions Wearing One Sentence

“Can I get extra of my dog’s medication before the storm” is really two questions with two owners.

The first is a quantity question and it belongs to the prescriber. How much is appropriate to have on hand is a medical judgment about a specific animal, and the federal text says so in almost those words. We will get to 21 CFR 1306.04(a) below.

The second is a legal question and it belongs to the schedule the drug sits in, the state you live in, and sometimes a plan or a pharmacy policy nobody has told you about. That question has published answers, which is what the rest of this page is.

Keeping them apart matters, because most of the frustration in this situation comes from asking the legal question of the person who owns the medical one, or the reverse. A pharmacist cannot decide that your dog should have a larger prescription. A veterinarian cannot rewrite your state’s schedule. Neither of them can move an insurer’s day-supply limit. Knowing which wall you are standing in front of is most of the work.

For the condition where this comes up most often, our seizure dog emergency kit covers the buffer arithmetic, the storage problem and what three named states publish about emergency refills during a declared disaster. This page sits underneath that one: it is the statutory reason the two-week standard is hard to reach for an entire class of drugs, whatever the condition.

Who Is Who Under the Statute

First, the frame. 21 U.S.C. 812(a): “There are established five schedules of controlled substances, to be known as schedules I, II, III, IV, and V.” The substances in each are listed at 21 CFR Part 1308. Which of the five your animal’s prescription sits in is the fact that determines nearly everything below, and it is a fact your pharmacy holds rather than one to deduce from an article.

Then three definitions, which do a surprising amount of work. Two of them contain a word most owners never expect to find in drug law.

Your veterinarian is a practitioner. 21 U.S.C. 802(21) defines the term to mean “a physician, dentist, veterinarian, scientific investigator, pharmacy, hospital, or other person licensed, registered, or otherwise permitted, by the United States or the jurisdiction in which he practices or does research, to distribute, dispense, conduct research with respect to, administer, or use in teaching or chemical analysis, a controlled substance in the course of professional practice or research.” Veterinarian is the third word in that list. A veterinary controlled-substance prescription is not an odd exception to a human-medicine statute; it is inside the definition.

You are the ultimate user, and the definition names animals. 21 U.S.C. 802(27) defines an ultimate user as “a person who has lawfully obtained, and who possesses, a controlled substance for his own use or for the use of a member of his household or for an animal owned by him or by a member of his household.”

Read that last clause again, because it answers a question owners ask nervously and rarely get a straight answer to. Congress contemplated a person lawfully holding a controlled substance for an animal they own. That is the category you are in when you have a labeled bottle in a kitchen cabinet with your dog’s name on it.

Everything in Part 1306 is written to ultimate users. 21 CFR 1306.01 states its own scope: “This part sets forth the process and procedures for dispensing, by way of prescribing and administering controlled substances to ultimate users. The purpose of such procedures is to provide safe and efficient methods for dispensing controlled substances while providing effective controls against diversion.”

Now the part that surprises people. We pulled the full text of 21 CFR Part 1306 from the eCFR versioner API for the title 21 edition of August 7, 2026, and searched it. The words “veterinarian” and “animal” do not appear anywhere in the part. Not once. The rules that govern a veterinary controlled-substance prescription are written entirely in the language of patients, practitioners and pharmacists, and they reach veterinary medicine through the definitions above rather than through any veterinary-specific provision.

That is worth holding onto for the rest of this page. When a rule sounds like it was written for a human patient, it usually was. That does not make it inapplicable. It makes it a rule whose application to a specific veterinary prescription is a question for the pharmacist filling it and the state board that licenses them.

Four Claims, Checked Line By Line

These four sentences circulate constantly, including in preparedness writing. Three of them are not federal rules. Here is each one against the text.

Claim one: “Schedules III through V are capped at five refills in six months”

Half right, and the half that is wrong is a whole schedule.

21 CFR 1306.22(a), in full: “No prescription for a controlled substance listed in Schedule III or IV shall be filled or refilled more than six months after the date on which such prescription was issued. No prescription for a controlled substance listed in Schedule III or IV authorized to be refilled may be refilled more than five times.”

Schedule III or IV. Twice. Schedule V is not in that sentence.

The statute behind it reads the same way. 21 U.S.C. 829(b), covering Schedule III and IV: “Such prescriptions may not be filled or refilled more than six months after the date thereof or be refilled more than five times after the date of the prescription unless renewed by the practitioner.” Then 829(c), the entire subsection Congress gave to Schedule V: “No controlled substance in schedule V which is a drug may be distributed or dispensed other than for a medical purpose.” No count. No clock.

This is exactly the case the neighbouring-subdivision rule exists for. Section 1306.22 sits inside a subject group headed “Controlled Substances Listed in Schedules III, IV, and V”. Its neighbours in that group, sections 1306.21, 1306.23, 1306.24 and 1306.25, each say Schedule III, IV, or V. Section 1306.22 alone says Schedule III or IV. Reading the group heading and assuming the section under it follows suit is precisely how the wrong version of this claim gets written.

DEA says the same thing in its own guidance, and says it plainly. The Practitioner’s Manual, 2023 Edition: “The CSA and DEA regulations do not address limits for a schedule V refill. The CSA only provides that a schedule V controlled substance may not be distributed or dispensed other than for a medical purpose. 21 U.S.C. 829(c). Consequently, a refill for a schedule V controlled substance is issued by a practitioner for a legitimate medical purpose acting in the usual course of their professional practice.”

Correction, stated plainly: the five-refill, six-month limit is a Schedule III and Schedule IV rule. Extending it to Schedule V in print, which is what the common version of this claim does, invents a federal limit that the statute and the regulation both decline to impose. Whether your state imposes one is a separate question with a separate answer, because 21 CFR 1307.02 leaves stricter state law standing.

Claim two: “Federal law caps dispensing at 30 to 60 days”

It does not. DEA states this twice, in two different manuals, in nearly the same words.

Practitioner’s Manual, 2023 Edition: “While some states and insurance carriers may limit the quantity of controlled substances dispensed, there are no express federal limits with respect to the quantities of drugs dispensed via a prescription. However, the amount prescribed must be consistent with the requirement that a prescription for a controlled substance be issued only for a legitimate medical purpose by a practitioner acting in the usual course of professional practice.”

Pharmacist’s Manual, 2022 Edition, which goes further and names where the 30 comes from: “Some states and many insurance carriers limit the quantity of controlled substances dispensed to a 30-day supply. Other states and pharmacies have limited the initial prescribing of opioids. Though there are no express federal limits with respect to the quantities of drugs dispensed via a prescription, to be valid, a prescription for controlled substances must only be for a legitimate medical purpose by a practitioner acting in the usual course of professional practice.”

So the 30-day number is real. It is just not federal, and the difference matters enormously to you, because a state rule, an insurer’s rule and a pharmacy’s own policy have three different appeal routes and three different people who can answer a question about them. “Federal law says 30 days” ends the conversation. “Which of those three is this” starts one.

Two day-counts do appear in Part 1306, and both are worth knowing about precisely so you do not mistake them for general caps.

21 CFR 1306.14(c) removes the ordinary pharmacy labeling requirement for a Schedule II drug “prescribed for administration to an ultimate user who is institutionalized”, and the first condition attached is “Not more than 7-day supply of the controlled substance listed in Schedule II is dispensed at one time”. 21 CFR 1306.24(c) does the same for Schedules III, IV and V, with the condition “Not more than a 34-day supply or 100 dosage units, whichever is less, of the controlled substance listed in Schedule III, IV, or V is dispensed at one time”.

Read what those sections are doing. They are not quantity caps on prescriptions. They are conditions a facility must satisfy to skip putting a patient label on a package for someone who is institutionalized and who, per the very next condition in each section, does not hold the drug before it is administered. Lifting the 34 out of that context and calling it a federal dispensing limit is a misreading, and it is a misreading that would have you asking your pharmacist about a rule that has nothing to do with your household.

Correction, stated plainly: there is no general federal quantity limit on a controlled-substance prescription. The prescriber decides the quantity within the legitimate-medical-purpose standard, and any hard number you run into is a state rule, a plan rule or a store policy. Find out which one, by name, before you accept it as fixed.

Claim three: “You cannot refill earlier than five days before you run out”

We could not find this rule in federal law, and we looked specifically for it.

Here is exactly what was searched, on August 11, 2026.

The complete text of 21 CFR Part 1306, pulled from the eCFR versioner API for the title 21 edition of August 7, 2026. Searched for “earlier than”: no match anywhere in the part. Searched for “five days” and “5 days”: one match, and it is a lesson in how easy this subject is to get wrong, because the match was the string “5 days” sitting inside “45 days” in 21 CFR 1306.07(f)(5), which is a condition on a pharmacy delivering a narcotic drug to a practitioner for administration in maintenance or detoxification treatment. Nothing to do with refilling anything, and nothing to do with a pet. A keyword hit is not a finding until you read the sentence it lives in. Then, separately, every day-count in the part was enumerated rather than searched for by keyword: 1306.11(d)(4)’s seven-day deadline for a practitioner to deliver the written prescription after authorizing an emergency oral Schedule II order, 1306.13’s 30-day and 72-hour partial-fill windows, 1306.12(b)’s 90-day multiple-prescription provision, the LTCF and terminal-illness 60-day validity in 1306.13(c), and the institutional labeling conditions quoted above. None of them is a bar on filling early.

The full text of the DEA Practitioner’s Manual, 2023 Edition, and the DEA Pharmacist’s Manual, 2022 Edition, searched for “early refill”, “too soon” and “five days”: no such rule appeared in either, and the only “5 days” hit in the Practitioner’s Manual is the schedule on which DEA emails registration renewal reminders to registrants. 21 U.S.C. 829 and 21 U.S.C. 844, read in full: nothing.

That is a statement about what those documents contain, and it is not a claim that no such rule exists anywhere. It plainly exists somewhere, because pharmacies apply it constantly. What the search establishes is where it does not live, and therefore who you should be asking. An early-fill window is characteristically a payer rule or a state rule, and both of those have a named owner: the plan administrator on your card, or your state board of pharmacy. If someone tells you a fill is too soon, “is that my plan or is that state law” is a fair and answerable question, and the two answers lead different places.

There is one federal provision that does control the date a prescription may be filled, and it is narrow and worth knowing. 21 CFR 1306.14(e): “Where a prescription that has been prepared in accordance with section 1306.12(b) contains instructions from the prescribing practitioner indicating that the prescription shall not be filled until a certain date, no pharmacist may fill the prescription before that date.” That is the do-not-fill-before instruction on a sequenced set of Schedule II prescriptions, written by the prescriber, and it is the prescriber’s own date rather than a general early-refill bar.

Correction, stated plainly: we did not locate a federal no-earlier-than-five-days refill rule in the sources named above. Treat any five-day rule you meet as a state or payer rule until someone tells you which, and ask them which.

Claim four: “Federal law requires a periodic exam to keep the prescription going”

The federal hook exists. The interval does not.

21 CFR 1306.04(a) is the whole federal test, and it is a standard rather than a schedule: “A prescription for a controlled substance to be effective must be issued for a legitimate medical purpose by an individual practitioner acting in the usual course of his professional practice. The responsibility for the proper prescribing and dispensing of controlled substances is upon the prescribing practitioner, but a corresponding responsibility rests with the pharmacist who fills the prescription.”

Not a month, not a year, no number of any kind. And the federal definition of a veterinarian-client-patient relationship, the one FDA uses for extralabel drug use at 21 CFR 530.3(i), is written the same way: “Such a relationship can exist only when the veterinarian has recently seen and is personally acquainted with the keeping and care of the animal(s) by virtue of examination of the animal(s), and/or by medically appropriate and timely visits to the premises where the animal(s) are kept.” Recently. Timely. Still no number.

The numbers are in state practice acts, and California’s is a good illustration because it was amended recently and it is unusually explicit. Business and Professions Code section 4826.6, as amended by Stats. 2025, Ch. 195, Sec. 6 (AB 1502) and effective January 1, 2026, defines the relationship the same qualitative way at subdivision (b), stating that a veterinarian has sufficient knowledge of the patient “if the veterinarian has recently seen, or is personally acquainted with, the care of the animal patient” by examining the animal in person, by synchronous audio-video, or by timely visits to the premises. Then subdivision (i) supplies what the federal text never does.

Subdivision (i)(1): “A veterinarian shall not prescribe a drug for a duration of time that is inconsistent with the medical condition of the animal patient or the type of drug prescribed.”

Subdivision (i)(2): a veterinarian who established the relationship in person or by premises visit “shall not prescribe a drug for a duration of time that is longer than one year from the date that the veterinarian examined the animal patient in person or visited the premises and prescribed the drug.”

And subdivision (i)(6), which has to be read together with the subdivision immediately above it rather than on its own. Paragraph (i)(3) grants the general telehealth permission: “Except as provided in paragraphs (4) to (8), inclusive, a veterinarian who practices veterinary medicine via telehealth may order, prescribe, or make available drugs, as defined in Section 11014 of the Health and Safety Code, in accordance with all relevant state and federal regulations.” Paragraph (6) is one of the carve-outs that “except” clause points at: “The veterinarian shall not order, prescribe, or make available a controlled substance, as defined in Section 4021, or xylazine, unless the veterinarian has performed an in-person physical examination of the animal patient or made medically appropriate and timely visits to the premises where the animal patient is kept.”

Read the two together and the shape is clear. California lets a veterinarian prescribe by telehealth in general, and then pulls controlled substances back out of that permission unless the veterinarian has been physically present with the animal or has made timely visits to the premises where it is kept. Quoting paragraph (6) without paragraph (3) would make it sound like a flat statewide rule about every prescription; quoting paragraph (3) without paragraph (6) would tell a reader that a video call can produce a controlled-substance prescription in California. Neither is what the section says.

For a household hoping to solve a supply problem with a video call before a storm, that is the sentence that matters. Whether your state draws the same line is your state’s question, and the place to ask it is the board that licenses veterinarians where you live.

Correction, stated plainly: the exam requirement is real, it is common, and it is state law rather than federal law. Nothing in 21 CFR 1306.04 sets an interval. When your clinic tells you the animal is due before it will authorize more, that is either your state’s rule or the practice’s own policy, and it is entirely fair to ask which, because one of those can be scheduled around and the other cannot be argued with.

What Actually Bounds the Reserve

With the folklore cleared, here is the real shape of the constraint. Four things, and the first one is the one nobody plans for.

The six-month clock, which is what actually ruins a season plan

Look at 1306.22(a) again, but this time at the first sentence rather than the second: “No prescription for a controlled substance listed in Schedule III or IV shall be filled or refilled more than six months after the date on which such prescription was issued.”

That is a calendar, not a count. It runs from the date the prescription was written and it does not care how many refills are left on the paper. A prescription issued in January with five refills authorized still stops being fillable in July, refills or no refills. 1306.22(e)(4) says what happens next: “The prescribing practitioner must execute a new and separate prescription for any additional quantities beyond the five-refill, six-month limitation.”

Sit with what that means for a household in a storm-exposed state. A prescription written at a January wellness visit stops being fillable around the start of July, which is early in hurricane season rather than after it. If nobody is watching the issue date, the reserve you thought you had is a piece of paper the pharmacy cannot act on, and you find that out on the phone during a watch.

So the single most useful thing on this page is probably the smallest: find the issue date on the prescription, add six months, and put that date on the same calendar as your kit rotation. Not the fill date. The date the veterinarian wrote it. Our pet emergency kit rotation checklist is where that date belongs, next to the expiry checks you already run, and the pet medication refill calculator handles the doses-remaining half of the same arithmetic.

Schedule II has no refill at all, and one narrow route past it

21 U.S.C. 829(a): “No prescription for a controlled substance in schedule II may be refilled.” 21 CFR 1306.12(a): “The refilling of a prescription for a controlled substance listed in Schedule II is prohibited.”

Not five refills. Not one. Each fill needs its own prescription.

There is one federal provision that softens this, and it is worth knowing about precisely so you understand what it is and is not. 21 CFR 1306.12(b)(1): “An individual practitioner may issue multiple prescriptions authorizing the patient to receive a total of up to a 90-day supply of a Schedule II controlled substance provided the following conditions are met”. Five conditions follow. Each prescription must be issued for a legitimate medical purpose in the usual course of practice. Each one after the first carries written instructions naming the earliest date a pharmacy may fill it. The practitioner must conclude that the arrangement “does not create an undue risk of diversion or abuse”. And two of the five conditions are about your state: “The issuance of multiple prescriptions as described in this section is permissible under the applicable state laws” and the practitioner must comply with “any additional requirements under state law.”

Then the regulation adds a paragraph that reads almost like a warning label, at 1306.12(b)(2): “Nothing in this paragraph (b) shall be construed as mandating or encouraging individual practitioners to issue multiple prescriptions or to see their patients only once every 90 days when prescribing Schedule II controlled substances. Rather, individual practitioners must determine on their own, based on sound medical judgment, and in accordance with established medical standards, whether it is appropriate to issue multiple prescriptions and how often to see their patients when doing so.”

This is not a route you ask for. It is a permission the regulation grants to the prescriber, conditioned on the prescriber’s own judgment and on your state’s law, and the regulation goes out of its way to say it is not encouraging anyone to use it. It is here so that if your veterinarian raises it, you know what it is, and so that you understand why “can you just write me 90 days” is a question with a real legal ceiling behind it rather than a matter of goodwill.

Partial fills, and the subsection that reaches Schedule V when its neighbour does not

This is the other place the neighbouring-subdivision rule pays off.

21 CFR 1306.23 covers partial filling for the same group of schedules that 1306.22 covers refills for, except that this one does include Schedule V: “The partial filling of a prescription for a controlled substance listed in Schedule III, IV, or V is permissible, provided that: (a) Each partial filling is recorded in the same manner as a refilling, (b) The total quantity dispensed in all partial fillings does not exceed the total quantity prescribed, and (c) No dispensing occurs after 6 months after the date on which the prescription was issued.”

So the six-month outer edge does reach Schedule V, through the partial-fill section, even though the refill section does not mention Schedule V at all. Two adjacent sections, two different schedule lists, in the same subpart. If you were going to read one subsection alone and generalize from it, this is the pair that would punish you for it.

Partial fills matter in a supply crunch for an ordinary reason: they are what happens when a pharmacy does not have the whole quantity in stock. In a mass evacuation, that is the normal case rather than the exception, and the total across all partial fills still cannot exceed what was prescribed.

The transfer rule, if you end up filling somewhere else

21 CFR 1306.25(a): “The transfer of original prescription information for a controlled substance listed in Schedule III, IV, or V for the purpose of refill dispensing is permissible between pharmacies on a one-time basis only. However, pharmacies electronically sharing a real-time, online database may transfer up to the maximum refills permitted by law and the prescriber’s authorization.” The section adds that the transfer “must be communicated directly between two licensed pharmacists.”

One time only, unless the two pharmacies share a live database. If you evacuate and transfer a refill to a pharmacy in another town, and then move again, you may have already spent the transfer. Knowing that in advance is the difference between planning a route and discovering a wall.

And then state law stacks on top of every line above

21 CFR 1307.02: “Nothing in this chapter shall be construed as authorizing or permitting any person to do any act which such person is not authorized or permitted to do under other Federal laws or obligations under international treaties, conventions or protocols, or under the law of the State in which he/she desires to do such act nor shall compliance with such parts be construed as compliance with other Federal or State laws unless expressly provided in such other laws.”

Everything federal on this page is a floor. Your state can be stricter on any of it, and states are. DEA’s Practitioner’s Manual, 2023 Edition, states the consequence directly when discussing partial fills: where a state has not changed its own rules to match a federal change, “the stricter state law applies until such time as the state makes a change. 21 CFR 1307.02.”

Which is the answer to the most common frustrated question in this whole area. When you read a federal rule and your pharmacy applies a different one, both can be correct at once, and the state one wins.

Gabapentin, and the Difference Between Scheduled and Monitored

Gabapentin gets its own section because it demonstrates the state layer better than anything else on this page: the federal answer and the answer where you live can be different words, and a reader who stops at the federal one will be confidently wrong.

Federally, it is not in the schedules. We pulled the full text of 21 CFR Part 1308 from the eCFR versioner API for the title 21 edition of August 7, 2026 and searched it: zero occurrences of the word gabapentin. We re-ran the same pull on August 19, 2026 against the newer title 21 edition of August 17, 2026, and the answer had not moved: zero occurrences of gabapentin, one of pregabalin. It also does not appear in DEA’s own “Controlled Substances - Alphabetical Order” list, the document whose footer is dated 25-Jun-26, which we read on August 11, 2026.

In some states, it is scheduled, and those states say so explicitly. Kentucky’s 902 KAR 55:015, current version effective 3-12-2026, states in its own text: “This administrative regulation further differs from the federal regulation, 21 C.F.R. 1308.14-1308.15, because it designates nalbuphine as a Schedule IV controlled substance and gabapentin as a Schedule V controlled substance.” And at Section 5(2): “The Cabinet for Health and Family Services designates the following as a Schedule V controlled substance: gabapentin.”

The same Kentucky regulation contains a second divergence that is even more directly relevant to a seizure household. It states that it “differs from the federal regulation, 21 C.F.R. 1308.14, because it designates pentazocine, barbital, methylphenobarbital, and phenobarbital as a Schedule III controlled substance. The federal regulation designates these substances as a Schedule IV controlled substance.” Federally, 21 CFR 1308.14 lists phenobarbital in Schedule IV, and DEA’s alphabetical list agrees. In Kentucky it is state Schedule III. Same drug, same bottle, two schedule numbers depending on which document you are reading. That is not a contradiction anybody needs to resolve; it is the federal floor and a stricter state on top of it, exactly as 1307.02 contemplates.

In other states, it is monitored without being scheduled, which is a genuinely different thing. The Minnesota Board of Pharmacy’s monitoring program publishes both categories. On controlled substances: “All schedule II-V controlled substances listed in Minnesota Statutes Sect. 152.02 are required to be reported to the MN PMP.” Then separately: “Minnesota has also identified drugs of concern that are required to be reported to the MN PMP. These are gabapentin and all formulations of butalbital.” The board’s own explanation of why keeps the two categories apart in a single sentence: “While gabapentin is not a controlled substance federally or in Minnesota, a rise in cases of gabapentin misuse was seen, especially in combination with opioids or other substances to enhance their effects.” The page cites Minnesota Statutes section 152.126 as the basis for the 2016 amendment that added gabapentin.

Reporting is not scheduling. A monitored-but-unscheduled drug does not pick up the refill limits in 1306.22 or the Schedule II prohibition in 1306.12(a). What it picks up is a record in a state database. Merging the two categories, which is what most writing on this subject does, produces confident sentences that are wrong in both directions.

And the map keeps moving, which is the whole reason a count is the wrong thing to carry away from this section. The most rigorous compilation we located is the dataset “Legal Landscape of Gabapentin Drug Scheduling and Required Prescription Drug Monitoring”, published on LawAtlas.org with a publication year of 2025 and cited on its own page to Katherine Gora Combs, Collin Stewart, Daniel Wacker and Juan Hincapie-Castillo, whose affiliations are printed there as the UNC Gillings School of Global Public Health and the UNC Injury Prevention Research Center. It covers, in its own words, “51 jurisdictions in the United States (50 states and the District of Columbia)” and captures policies that either “classify gabapentin as a schedule V controlled substance or mandate reporting of gabapentin prescriptions in jurisdiction-level prescription drug monitoring programs (PDMPs).” We re-read its currency fields on August 19, 2026 and they had not moved: Dataset Valid From January 1, 2016, Dataset Updated Through December 31, 2024.

A correction to what this page previously said about the companion article

On August 11, 2026 this page reported that the peer-reviewed article behind that dataset could not be opened, and the sentence we published overstated what had actually happened. The corrected version, with the routes named.

The route that failed was the publisher’s. The Elsevier article page for the International Journal of Drug Policy returned an HTTP 403 to automated retrieval on August 11, 2026, with a bot-challenge body rather than the article. We checked it again on August 19, 2026 and got the same 403.

The route that works is the open-access one, and we did not try it on August 11. The National Library of Medicine hosts the accepted manuscript at PubMed Central under the identifier PMC12676011. That address returned HTTP 200 on August 19, 2026, and we have now read the article in full.

One blocked route was never evidence that a paper is unavailable, and writing it as though it were is a mistake we would rather correct in public than quietly delete. What follows is what the article says, now that we have read it.

What the article establishes, and the two limits it puts on itself

The article is Gora Combs, Vickers-Smith, Stewart, Wacker and Hincapie-Castillo, “A Comprehensive Analysis of Jurisdiction-Specific Laws Related to Scheduling or Required Prescription Drug Monitoring of Gabapentin in the United States, 2016–2024”, International Journal of Drug Policy 2025;147:105064. Note that the author list is not identical to the dataset’s: the article carries five authors where the dataset page credits four, and the added name is Rachel Vickers-Smith, second in the article’s own order, whose affiliation is printed there as the Department of Epidemiology and Environmental Health at what the article abbreviates as the UK College of Public Health, in Lexington, Kentucky.

Its abstract states the window in its own words. The analysis was conducted “across 51 jurisdictions in the United States from January 2016 through December 2024.” Its Figure 1 caption states the headline result: “As of December 31, 2024, 7 jurisdictions classify gabapentin as a schedule V controlled substance and mandate reporting in the jurisdiction’s prescription drug monitoring program and 17 mandate reporting without a controlled substance designation.” Its Table 1 lists eight states rather than seven, and the results text explains the difference: “One of these eight jurisdictions (Michigan) scheduled and required reporting of gabapentin to the PDMP and then subsequently descheduled and removed the reporting requirement during the study period.” Table 1 also carries a note under it, which matters if you go looking for any of these dates yourself: “Each state’s effective date listed in this table is the effective date of the first statute or regulation that scheduled gabapentin. This may not be the effective date of the current citation as of December 31, 2024.”

First limit: it is a study of human prescribing, and it says so. Its methods state: “We excluded other policies related to gabapentin, such as those focused on workers compensation, traditional Chinese or naturopathic medicine, or veterinary uses, because those laws were not explicitly related to scheduling or mandated prescription reporting in the medical setting.” Its second coding question is phrased “Does the jurisdiction require reporting of gabapentin prescriptions for human consumption in the jurisdiction’s prescription drug monitoring program (PDMP)?” So the seventeen reporting-only jurisdictions in that headline are an answer to a human-prescribing question. Whether a veterinarian has to report an animal patient’s prescription to a particular state’s monitoring program is a different question, it varies by state, and nothing on this page answers it. Do not read the number 17 as a number about animals.

Second limit: it stops at the end of 2024, and 2026 has already moved past it. This is not a criticism of the article, which is accurate for the window it claims. It is the reason a dated compilation cannot be reprinted as a current list, and we can now show that rather than assert it.

Montana is the demonstration. The word Montana does not appear anywhere in that article; a full-text search of the PubMed Central deposit on August 19, 2026 returned zero occurrences. Montana schedules gabapentin today. Montana Code Annotated 50-32-232, headed “Specific dangerous drugs included in Schedule V”, read on the Montana Legislature’s own site on August 19, 2026, opens its depressants subsection with the qualifier “Unless specifically exempted or excluded or unless listed in another schedule” and then lists at (3)(c): “gabapentin, also known as 1-(aminomethyl)cyclohexaneacetic acid.” The section’s history line ends “amd. Sec. 1, Ch. 7, L. 2025.” Directly beneath that history line the Legislature prints its own caution about the version we read, and it belongs here with the citation: “The Internet version of the Montana Code Annotated is provided as a research tool to users of the Code. In case of inconsistencies resulting from omissions or other errors, the printed version will prevail.”

The date on that amendment is worth pinning down, because there are two different accusations available here and only one of them is true. It would be wrong to say the compilation overlooked a state inside its own window. What is true is that it stops before the change happened. Internet Archive captures of that exact Montana page taken on January 22, 2025 and May 19, 2025 contain no occurrence of the word gabapentin and end their history line at the 2023 amendment. The capture taken on March 15, 2026 carries both the drug and the 2025 amendment. Montana became a scheduling state after the study window had closed. The best compilation in the literature is therefore correct for the period it covers and incomplete for the period you are living in, which is exactly what any dated list becomes and exactly why the two checks at the end of this section are the instruction rather than the table.

The eight states we opened and read ourselves

Here is what we can stand behind: on August 19, 2026 we opened each of these states’ current controlled substances schedule and read the entry. One primary source per row, one read date per row, and the form the entry takes in that document. Two rows carry a retrieval caveat, set out immediately after the table.

State	Primary source	The entry, in that document’s own words	Read
Alabama	Ala. Admin. Code ch. 420-7-2, Appendix Controlled Substances List (420-7-2-A)	Schedule V depressants, item 8, “Gabapentin”, carrying the parenthetical “(State Control Nov. 18, 2019)”	2026-08-19
Kentucky	902 KAR 55:015, Section 5(2)	“The Cabinet for Health and Family Services designates the following as a Schedule V controlled substance: gabapentin.”	2026-08-19
Montana	Mont. Code Ann. 50-32-232(3)(c)	“gabapentin, also known as 1-(aminomethyl)cyclohexaneacetic acid.”	2026-08-19
North Dakota	N.D. Cent. Code 19-03.1-13(5)(g)	“Gabapentin [2-[1-(aminomethyl) cyclohexyl] acetic acid].”	2026-08-19
Tennessee	Tenn. Comp. R. and Regs. 0940-06-01-.05(4)(d), current rule, amendments effective 5/30/2024. See caveat below	“Gabapentin [1-(aminomethyl)cyclohexaneacetic acid]”	2026-08-19
Utah	Utah Code 58-37-108(2)(e)(iii), effective May 6, 2026, renumbered from 58-37-4. See caveat below	“Gabapentin.” on its own, with no chemical name and no exception clause attached	2026-08-19
Virginia	Va. Code 54.1-3454, subdivision 3	“Gabapentin [1-(aminomethyl)cyclohexaneacetic acid];”	2026-08-19
West Virginia	W. Va. Code 60A-2-212(f)	“(f) Other substances: Gabapentin; Pregabalin; Cenobamate; and Lasmiditan.”	2026-08-19

The two caveats, named rather than buried. Tennessee’s current chapter PDF on the Secretary of State’s own file host returned an HTTP 403 to us. We read the current rule on Cornell’s Legal Information Institute mirror instead, which carries the amendment history ending effective 5/30/2024, and cross-checked the entry against the Secretary of State’s January 2023 revision PDF at that same host, which did return 200. The two reconcile exactly. Utah is the row that moved underneath its own citation. The undated section page at the Legislature’s site returns a script shell with no schedule text in it to automated retrieval, so the text is readable only through a dated version address. The version effective May 7, 2025 carries the entry at 58-37-4(2)(e)(iii) and prints its own end marker directly beneath the effective date: “(Renumbered 5/6/2026)”. So 58-37-4 is not the current citation, and a page that reprinted it as one would be sending readers to a superseded number. The section it became is 58-37-108, whose history line reads “Renumbered and Amended by Chapter 362, 2026 General Session” and whose subsection 58-37-108(2)(e)(iii) is the one-word entry in the table above. We confirmed that by three independent routes on August 19, 2026: the dated HTML version page, the section XML, which numbers that subsection 58-37-108(2)(e)(iii) in its own markup, and the section PDF. One thing we still cannot settle. The Legislature’s chapter page for 58-37 prints a further “(Renumbered 7/1/2026)” against the chapter itself, and no section-level version under that date was retrievable to us, so we do not know whether the number moves again. Cite 58-37-108 rather than 58-37-4, and if Utah is your state, open the chapter in a browser and check the number before you rely on it.

Two scope notes belong with that table rather than under it, because they change how a row reads.

Six of the eight place gabapentin inside a list that opens with an exception clause, in two different wordings. Virginia and West Virginia each open with “Unless specifically excepted or unless listed in another schedule”; Alabama, Montana, North Dakota and Tennessee each open with “Unless specifically exempted or excluded or unless listed in another schedule”. Kentucky and Utah name the drug flat, with no such clause attached. That clause is the same warning that heads most of the federal drug lists, and it is the reason formulation and combination can move an answer that looks settled.

The wording is set paragraph by paragraph rather than state by state, which is worth knowing before you go looking for it. Alabama’s own Schedule V uses both: its narcotic-drugs paragraph at (b) and its stimulants paragraph at (d) each read “Unless specifically excepted or unless listed in another schedule”, while the depressants paragraph at (e), the one that carries gabapentin, reads “Unless specifically exempted or excluded or unless listed in another schedule”. Read the paragraph your drug is actually in. Alabama adds one more clause of its own directly after the Schedule V list: “Any drug product exempted from control by the Federal Drug Enforcement Administration will also be exempted from the Alabama Controlled Substances List unless the State Committee of Public Health takes additional action.”

Note also where West Virginia files it. Gabapentin is not in that state’s depressants paragraph; it is in a separate paragraph headed “Other substances”, alongside pregabalin, cenobamate and lasmiditan. If you go looking for it under depressants in West Virginia you will not find it and may conclude the wrong thing.

Now the four things this table is not, stated plainly because a table invites a reader to treat it as complete.

It is not a complete list. We read these eight because a dated compilation and a live 2025 amendment pointed at them, and we read Michigan’s statute for the reason given below. That is nine of fifty-one jurisdictions. We did not read the other forty-two, a ninth scheduling state is not ruled out by anything on this page, and we make no claim in either direction about any state not named here. Secondary lists circulating online do name additional states. We are not repeating those names, because none of them has been held to the standard the eight rows above were held to, which is one primary source opened and read on a stated date, and because a name on an undated list assembled by nobody in particular is not evidence about a state’s law in either direction.

It is not a reporting list. Scheduling and monitoring are separate constraints, as the Minnesota material above shows. This table is only about scheduling. It says nothing about which states require a gabapentin prescription to be reported to a monitoring program.

It is not, by itself, a statement about what a veterinary prescription triggers. These are entries in state controlled substances schedules. What a given state’s scheduling changes in practice for a veterinary prescription, a veterinary practice’s recordkeeping, or a pharmacy filling for an animal is a further state question, and the peer-reviewed source discussed above removed veterinary policies from its scope on purpose, so it cannot answer it. One of the eight states does answer it, and that document has its own section immediately below.

It is not durable. Montana was added in 2025 and Michigan was removed in 2024. A table like this is a photograph with a date printed on it, which is why the two checks below are the actual instruction and the table is only the evidence that they are necessary.

What scheduling actually changes at a veterinary practice, in one state’s own words

The table above is a list of legal entries, and a legal entry is not the same as a consequence. Only one of the eight states published a document telling veterinarians what its scheduling change did to them, and it is worth reading, because it is the closest thing on this page to an answer to the question a reader in a scheduling state actually has.

Virginia’s Board of Veterinary Medicine published a one-page notice headed “Scheduling of Gabapentin” when the change took effect. The file’s own creation date is June 21, 2019, and we read it on August 19, 2026. On the practice’s side it states: “On July 1, 2019, veterinary establishments that possess gabapentin must take a complete and accurate inventory of this drug at the opening of business in accordance with §54.1-3404 and maintain compliance with 18VAC150-20-190 for a Schedule V controlled substance.”

On the pharmacy’s side it points at Virginia’s pharmacy regulations at 18VAC110-20-320 and states that under them a Schedule V controlled substance “shall not be dispensed or refilled more than six months after the date on which such prescription was issued, nor may it be refilled more than five times.” That is the same six-month, five-refill shape as 21 CFR 1306.22(a) higher up this page, arriving through state law at a drug federal law does not schedule at all. The two sentences that follow it in the notice are the ones that decide a real case, so they belong here with it: “Dispensers with active prescriptions on file with a date of issuance greater than six months or that have been refilled five times or more will be considered expired. While a prescriber should authorize no more than five refills of gabapentin beginning July 1, 2019, should a pharmacist receive a prescription authorizing more than five refills, the prescription will still expire six months after the date of issuance or after five refills, whichever occurs first.” In Virginia, on that notice’s reading, a prescription written with more refills than a Schedule V allows does not buy the extra refills.

The notice also closes the registration question a prescriber would reasonably ask: “While this scheduling action occurred under State law, the Drug Enforcement Administration (DEA) has not yet scheduled gabapentin. Therefore, a prescriber is not required to hold a DEA registration in order to possess or prescribe gabapentin.”

Three limits, so that section is not read as more than it is. It is one state of the eight. It is a 2019 notice rather than a current restatement, so treat it as evidence of what a scheduling change does rather than as today’s Virginia procedure, and confirm anything you act on with the board. And we did not find the equivalent notice for any of the other seven states, which is a gap in our search rather than a finding about those states. It also says nothing about monitoring-program reporting, which is the separate question set out at the end of this page.

One state moved the other way

Michigan scheduled gabapentin and then removed it, and the removal is documented in the state’s own material. The Data Submission Guide for Dispensers for the Michigan Automated Prescription System, July 2024, Version 4.0, published under the state’s Department of Licensing and Regulatory Affairs and written by the monitoring program’s vendor, states: “Effective May 28, 2024, Gabapentin was removed from Schedule V controlled substance in Michigan and should not be reported to MAPS.” The same document’s change log records the edit against version 4.0, dated 07/22/2024, in a table cell that carries no terminal punctuation of its own: “Removed Gabapentin as a Schedule V controlled substance reporting requirement per state request”. The peer-reviewed article’s own Table 1, discussed earlier in this section, gives the same date from an independent direction: in the column where every other state’s row prints a current citation, Michigan’s row prints “Rescinded May 28, 2024”. Michigan’s statutory Schedule 5 at MCL 333.7220, read on August 19, 2026 in a version the Legislature marks complete through Public Act 91 of 2026, does not contain the word gabapentin.

A vendor-written program guide is not the same authority as a state rule, and we are naming its authorship rather than presenting it as the state speaking. What makes the date usable is that two documents produced by different people, for different purposes, print the same one.

So: two checks, and they beat any table including ours

Look up your state’s own controlled substances schedule, published by whichever agency holds it where you live, and look up your state monitoring program’s list of reportable drugs, which is usually published by the board of pharmacy. Those two documents together tell you whether the drug in your cabinet is scheduled, monitored, both, or neither in the state you actually live in. Done once, in a quiet month, they settle it for your household, and they stay right when a table in an article has gone stale.

None of this is a reason to change or stop a medication, and this page is not suggesting you switch to something unscheduled. What drug your animal takes is a decision for the veterinarian who is treating it.

The Label Is the Legal Document, and Federal Law Says What Goes On It

Owners underrate the label. It is the single densest record you own about a prescription, and its contents are specified.

For a Schedule III, IV or V drug filled at a pharmacy, 21 CFR 1306.24(a) requires the label to show “the pharmacy name and address, the serial number and date of initial filling, the name of the patient, the name of the practitioner issuing the prescription, and directions for use and cautionary statements, if any, contained in such prescription as required by law.” The Schedule II equivalent at 1306.14(a) is nearly identical and adds the date of filling.

Then there is a second labeling rule, and it applies whenever a veterinarian prescribes a drug for an animal outside the drug’s approved labeling, including a product approved for humans. That practice is governed by 21 CFR Part 530, whose scope section states: “This part applies to the extralabel use in an animal of any approved new animal drug or approved new human drug by or on the lawful order of a licensed veterinarian within the context of a valid veterinary-client-patient relationship.” For nonfood animals, 530.30(a) states that “extralabel use of animal and human drugs is permitted in nonfood-producing animal practice except when the public health is threatened.”

Where that applies, 21 CFR 530.12 specifies what the labeling must carry, and the list is exactly the list you would want in a shelter parking lot at midnight. Paragraph (a) requires “The name and address of the prescribing veterinarian. If the drug is dispensed by a pharmacy on the order of a veterinarian, the labeling shall include the name of the prescribing veterinarian and the name and address of the dispensing pharmacy, and may include the address of the prescribing veterinarian”. Paragraph (b) requires “The established name of the drug or, if formulated from more than one active ingredient, the established name of each ingredient”. And paragraph (c) requires “Any directions for use specified by the veterinarian, including the class/species or identification of the animal or herd, flock, pen, lot, or other group of animals being treated, in which the drug is intended to be used; the dosage, frequency, and route of administration; and the duration of therapy”.

Three practical consequences.

Photograph the label, both sides, before hurricane season. It carries the prescribing veterinarian’s name, the dispensing pharmacy’s name and address, the prescription serial number, and the regimen. That is most of what a receiving pharmacy or an unfamiliar emergency clinic needs to identify what your animal is on. Our paper versus digital pet medical records comparison covers what form to keep those images in when the phone is the thing that fails, and reconstructing pet records when the clinic is gone covers the harder case where the originating practice no longer exists.

Think hard before decanting into a pill organizer for an evacuation. Every identifier the two labeling rules above require lives on the container the pharmacy dispensed. A weekly organizer carries none of it, and loose tablets inside one arrive at an unfamiliar clinic or a shelter intake desk with nothing attached establishing what they are or who prescribed them.

The issue date you need for the six-month clock may not be on the label at all. The label carries the date of filling. The six-month limit in 1306.22(a) runs from the date the prescription was issued. Those are frequently different dates, and the second one is the one that expires your paper. Ask the pharmacy for the issue date and write it down.

Possession and Travel, and What a Labeled Bottle Does Not Do

Federal possession law is short and it does contemplate you.

21 U.S.C. 844(a) opens: “It shall be unlawful for any person knowingly or intentionally to possess a controlled substance unless such substance was obtained directly, or pursuant to a valid prescription or order, from a practitioner, while acting in the course of his professional practice, or except as otherwise authorized by this subchapter or subchapter II.”

Read that alongside 802(27), quoted near the top of this page, with its clause about “an animal owned by him or by a member of his household”, and alongside 802(21), which puts veterinarian inside the definition of practitioner. The three fit together into a coherent picture: a controlled substance obtained on a veterinarian’s valid prescription for your own animal is inside the exception in 844(a), and the ultimate-user definition names that exact situation.

Now the part where the federal picture stops. 21 CFR 1307.02 preserves state law, and possession of prescription medication is an area where states legislate independently. What a given state requires by way of an original labeled container, and how it treats a prescription written by an out-of-state veterinarian, are state questions. This page is not going to tell you that a labeled bottle protects you everywhere, because we did not find a source that establishes that and it is not the kind of claim that should be inferred.

On air travel, screening is a separate authority again. TSA’s published answer to the question of traveling with medication, read on August 11, 2026, is: “All passenger items must undergo security screening. It is recommended that medication be clearly labeled to facilitate the screening process.” It continues: “You may bring medically necessary liquids, medications and creams in excess of 3.4 ounces or 100 milliliters in your carry-on bag. Remove them from your carry-on bag to be screened separately from the rest of your belongings.” TSA’s “Medications (Pills)” entry, last updated October 9, 2024, lists pills as allowed in both carry-on and checked bags.

Notice what that guidance is and is not. Labeling is recommended to make screening go smoothly. It is guidance about a checkpoint, not a statement about whether possession is lawful in a given state, and TSA is not the agency that would make that statement. If you are flying out of an evacuation zone with an animal, flying out with a pet during an evacuation covers the rest of that problem, and crossing state lines with a health certificate covers the paperwork side of a drive.

Practical version, and it is short. Keep the medication in the container the pharmacy dispensed it in. Keep the written prescription record with it rather than in a different bag. Carry it with you rather than in a vehicle you may have to abandon. And if your route crosses several states, spend ten minutes before the season looking at what those states publish, rather than finding out at a checkpoint.

The Conversation That Is Actually Legitimate

Here is what this page will not give you: a phrase that gets a larger quantity, a way to time a fill, a second prescriber, a pharmacy more likely to say yes. Those are not preparedness. They are the behaviour the diversion controls in Part 1306 exist to catch, and asking a veterinarian or a pharmacist for them puts a licensed professional in a position they cannot help you from.

What is legitimate is a set of questions with real answers, asked at a routine appointment in a quiet month. Every one of these maps onto something quoted above.

“Which schedule is this drug in?” The schedule determines almost everything else on this page. It is a fact your pharmacy holds and can tell you in seconds, and it is not something to work out from a website: the drug lists in 21 CFR 1308.14 mostly open with the qualifier “Unless specifically excepted or unless listed in another schedule”, which is the regulation itself warning that formulation and combination can move the answer. Write the schedule in your pet binder.

“What date was the current prescription issued, and when does it stop being fillable?” This is the six-month question from 1306.22(a), and the issue date is often not the date printed on your bottle. Get the actual date and calendar it.

“How many refills are left on it right now?” 21 CFR 1306.22(c) requires that certain information “must be retrievable by the prescription number”, and its list includes “The quantity dispensed” and “The total number of refills for that prescription”. This is a question their system is built to answer.

“When is my animal next due, and is that your practice’s policy or my state’s rule?” From claim four above: 1306.04 sets no interval, and California’s statute shows what a state one looks like. A practice policy can often be scheduled around. A state requirement cannot be negotiated, but knowing which it is tells you whether to book an appointment or stop asking.

“If I need to fill this somewhere else after evacuating, what does that take?” 1306.25(a) makes a paper transfer a one-time event between two pharmacies unless they share a live database. Whether your pharmacy is part of a chain with a shared real-time system is a genuinely useful thing to know before you drive.

“Given all of that, what size of reserve do you think is appropriate for this animal, and what would you need from me to write it?” This is the only quantity question on the list, it is addressed to the only person who can answer it, and it is asked as a medical question rather than a legal one. 21 CFR 1306.04(a) puts the responsibility for the amount squarely on the prescriber, and the DEA manuals say twice that federal law does not supply a number. So the answer genuinely is theirs to give, and they may say no, and no is a legitimate professional answer rather than an obstacle to route around.

“What does this practice do during a declared emergency?” State emergency provisions do exist. Our seizure dog emergency kit page quotes three states’ published emergency-refill provisions in their own words, including one whose limits differ by schedule, and it also documents an honest gap in that material about how such rules reach a veterinary prescription. Ask your own clinic and your own pharmacy what they would do, and write both answers down where you will find them under stress.

The reason to run this list in a calm month is simple. Every one of these has a settled answer that somebody can look up in a minute when nothing is happening, and none of them can be resolved at speed when a watch is posted and the phones are busy. Our hurricane season pet prep calendar has the slot for it, and when to buy pet emergency supplies covers the wider timing question this sits inside.

What We Could Not Establish

Stated plainly, so that nothing on this page reads as more settled than it is.

Whether a federal early-fill rule exists somewhere we did not look. We searched the full text of 21 CFR Part 1306 for the title 21 edition of August 7, 2026, the DEA Practitioner’s Manual 2023 Edition, the DEA Pharmacist’s Manual 2022 Edition, and 21 U.S.C. 829 and 844, and found no no-earlier-than-five-days provision. That is what those documents contain. It is not a finding that no such rule exists in any federal source.

A complete list of the states that schedule gabapentin. We publish eight states above because we opened each state’s own schedule and read the entry on August 19, 2026. We do not publish a total, and we make no claim about any state we did not open. The reason has changed since this page first ran, and the new reason is stronger than the old one. The original reason given here was partly a retrieval failure, and it was overstated: this page said the companion peer-reviewed article had returned a 403, when what had returned a 403 was one route to it, the publisher’s site. The open-access deposit at PubMed Central was reachable, we have now read the article, and the correction is set out in full in the gabapentin section above. The reason that survives is the one we can now demonstrate. That article states its own coverage as running through December 31, 2024; Montana added gabapentin to its Schedule V by a 2025 amendment and does not appear in the article at all; so the best compilation in the literature is provably behind the present, and any total taken from it would be wrong today. A total taken from our own reading would be wrong too, because we read eight schedules and there are fifty-one.

Whether a veterinarian must report an animal patient’s gabapentin prescription to a state monitoring program. We did not establish this for any state. The peer-reviewed source on gabapentin monitoring excluded veterinary policies from its scope in its own methods and coded its reporting question for human consumption. Virginia’s Board of Veterinary Medicine notice, quoted in the gabapentin section above, is the one veterinary-specific document we located, and it addresses inventory, refill limits and DEA registration rather than monitoring-program reporting. So that leaves a real question with no answer on this page, and your state board of pharmacy is the place to put it.

Whether any state publishes an emergency-quantity provision specifically written for veterinary controlled-substance prescriptions. Emergency refill provisions exist in state law, and our seizure-medication page quotes three of them from the states’ own notices. Whether one of them is written specifically for a veterinary prescription rather than reaching it by implication is not something we have established here, and it is a good question to put to your state board of pharmacy directly.

How your specific prescription is treated. Nothing on this page tells you which schedule your pet’s drug is in. Formulation, combination and state all change that answer, and the qualifier that heads most of the drug lists in 21 CFR 1308, warning that a substance may be specifically excepted or listed in another schedule, exists precisely because of it. Your pharmacy holds the answer for your bottle.

Your Controlled-Medication Checklist

• Ask the pharmacy which schedule your pet’s medication is in, and write it in the pet binder next to the drug name.
• Get the issue date of the current prescription, not the fill date, and add six months to it if the drug is Schedule III or IV. Put that date on the same calendar as your kit rotation.
• Ask how many refills remain right now. The pharmacy is required to be able to retrieve that by prescription number.
• Find out when the animal is next due for an exam, and ask whether that timing is the practice’s policy or your state’s rule.
• Ask your veterinarian, as a medical question at a routine visit, what size reserve is appropriate for this animal and what they would need in order to write it. Accept a no as an answer.
• Ask whether your pharmacy shares a real-time database with other locations, because a paper transfer between unconnected pharmacies is a one-time event.
• If a day-supply limit is quoted at you, ask whose limit it is: state law, the plan, or store policy. Write down which.
• Look up your own state’s controlled substances schedule and your state monitoring program’s reportable-drug list once, and file both answers. Do not rely on any article’s state list, including the dated eight-state table above and any list you read last year.
• Photograph the full label, both sides, and store it with your records rather than only on the phone.
• Keep the medication in the pharmacy’s own container for any evacuation, and carry the written prescription record in the same bag.
• Ask the clinic and the pharmacy, in a quiet month, what each of them does during a declared state emergency, and write both answers in the binder.
• Do not ration, split, stretch or stop doses on your own judgment because supply looks short. That is a call to the clinic, not a decision to make in a parking lot.

Where to Go Next

This page is the legal-constraint spoke of our pet evacuation kits pillar. The rest of the medication problem splits three ways.

The condition-specific version. The seizure dog emergency kit builds the actual buffer for the household where this question comes up most, with the dose arithmetic, three states’ published emergency-refill provisions and the storage problem worked through on labeled sources. If your animal is on several prescriptions at once, senior dog emergency kit covers managing a multi-drug regimen through an evacuation.

The storage half. A reserve you legally hold can still be destroyed by the environment you carry it in. Pet medication and a refrigeration outage covers the cold-chain case, and the insulin cooler and diabetic pet kit covers the hardware where a temperature excursion is the whole risk.

The records half. Paper versus digital pet medical records settles what form to carry the label images and prescription details in, the pet travel document organizer gives you somewhere to put them, and reconstructing pet records when the clinic is gone is the page for after a practice has been destroyed and you are starting from nothing.

Then do the smallest thing on this page, this week, while nothing is happening. Call the pharmacy and ask two questions: which schedule, and what date was it issued. Two sentences, one phone call, and the answer to the question that would otherwise stop you in September is already written down.